Glucose as a prognostic factor in ovarian carcinoma

Donald M. Lamkin, Douglas R. Spitz, Mian M K Shahzad, Bridget Zimmerman, Daniel J. Lenihan, Koenraad De Geest, David M. Lubaroff, Eileen H. Shinn, Anil K. Sood, Susan K. Lutgendorf

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator, In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time In ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients. METHODS: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. RESULTS: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2,O1; P = .O2) and DFI (HR, 2.48; P = .OO1) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. CONCLUSIONS: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)1021-1027
Number of pages7
JournalCancer
Volume115
Issue number5
DOIs
StatePublished - Mar 1 2009
Externally publishedYes

Fingerprint

Carcinoma
Glucose
Survival
Ovarian Neoplasms
Recurrence
Facilitative Glucose Transport Proteins
Proportional Hazards Models
Disease-Free Survival
Medical Records
Neoplasms
Body Mass Index
Referral and Consultation
Multivariate Analysis
Research
Proteins

Keywords

  • Cancer
  • Glucose
  • Ovarian cancer
  • Prognosis
  • Recurrence
  • Survival rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lamkin, D. M., Spitz, D. R., Shahzad, M. M. K., Zimmerman, B., Lenihan, D. J., De Geest, K., ... Lutgendorf, S. K. (2009). Glucose as a prognostic factor in ovarian carcinoma. Cancer, 115(5), 1021-1027. https://doi.org/10.1002/cncr.24126

Glucose as a prognostic factor in ovarian carcinoma. / Lamkin, Donald M.; Spitz, Douglas R.; Shahzad, Mian M K; Zimmerman, Bridget; Lenihan, Daniel J.; De Geest, Koenraad; Lubaroff, David M.; Shinn, Eileen H.; Sood, Anil K.; Lutgendorf, Susan K.

In: Cancer, Vol. 115, No. 5, 01.03.2009, p. 1021-1027.

Research output: Contribution to journalArticle

Lamkin, DM, Spitz, DR, Shahzad, MMK, Zimmerman, B, Lenihan, DJ, De Geest, K, Lubaroff, DM, Shinn, EH, Sood, AK & Lutgendorf, SK 2009, 'Glucose as a prognostic factor in ovarian carcinoma', Cancer, vol. 115, no. 5, pp. 1021-1027. https://doi.org/10.1002/cncr.24126
Lamkin DM, Spitz DR, Shahzad MMK, Zimmerman B, Lenihan DJ, De Geest K et al. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar 1;115(5):1021-1027. https://doi.org/10.1002/cncr.24126
Lamkin, Donald M. ; Spitz, Douglas R. ; Shahzad, Mian M K ; Zimmerman, Bridget ; Lenihan, Daniel J. ; De Geest, Koenraad ; Lubaroff, David M. ; Shinn, Eileen H. ; Sood, Anil K. ; Lutgendorf, Susan K. / Glucose as a prognostic factor in ovarian carcinoma. In: Cancer. 2009 ; Vol. 115, No. 5. pp. 1021-1027.
@article{475f02b466b3413991e23f48a0529d13,
title = "Glucose as a prognostic factor in ovarian carcinoma",
abstract = "BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator, In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time In ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients. METHODS: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. RESULTS: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2,O1; P = .O2) and DFI (HR, 2.48; P = .OO1) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. CONCLUSIONS: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma.",
keywords = "Cancer, Glucose, Ovarian cancer, Prognosis, Recurrence, Survival rate",
author = "Lamkin, {Donald M.} and Spitz, {Douglas R.} and Shahzad, {Mian M K} and Bridget Zimmerman and Lenihan, {Daniel J.} and {De Geest}, Koenraad and Lubaroff, {David M.} and Shinn, {Eileen H.} and Sood, {Anil K.} and Lutgendorf, {Susan K.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1002/cncr.24126",
language = "English (US)",
volume = "115",
pages = "1021--1027",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Glucose as a prognostic factor in ovarian carcinoma

AU - Lamkin, Donald M.

AU - Spitz, Douglas R.

AU - Shahzad, Mian M K

AU - Zimmerman, Bridget

AU - Lenihan, Daniel J.

AU - De Geest, Koenraad

AU - Lubaroff, David M.

AU - Shinn, Eileen H.

AU - Sood, Anil K.

AU - Lutgendorf, Susan K.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator, In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time In ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients. METHODS: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. RESULTS: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2,O1; P = .O2) and DFI (HR, 2.48; P = .OO1) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. CONCLUSIONS: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma.

AB - BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator, In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time In ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients. METHODS: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. RESULTS: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2,O1; P = .O2) and DFI (HR, 2.48; P = .OO1) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. CONCLUSIONS: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma.

KW - Cancer

KW - Glucose

KW - Ovarian cancer

KW - Prognosis

KW - Recurrence

KW - Survival rate

UR - http://www.scopus.com/inward/record.url?scp=61449245594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449245594&partnerID=8YFLogxK

U2 - 10.1002/cncr.24126

DO - 10.1002/cncr.24126

M3 - Article

VL - 115

SP - 1021

EP - 1027

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -